The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Abstract
The anti-CD38 monoclonal antibody SAR650984 (SAR) is showing promising clinical activity in treatment of relapsed and refractory multiple myeloma (MM). Besides effector-mediated antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity, we here define molecular mechanisms of SAR-directed MM cell death and enhanced anti-MM activity triggered by SAR with Pomalidomide (Pom). Without Fc-cross-linking agents or effector cells, SAR specifically induces homotypic aggregation (HA)-associated cell death in MM cells dependent on the level of cell surface CD38 expression, actin cytoskeleton and membrane lipid raft. SAR and its F(ab)'2 fragments trigger caspase 3/7-dependent apoptosis in MM cells highly expressing CD38, even with p53 mutation. Importantly, SAR specifically induces lysosome-dependent cell death (LCD) by enlarging lysosomes and increasing lysosomal membrane permeabilization associated with leakage of cathepsin B and LAMP-1, regardless of the presence of interleukin-6 or bone marrow stromal cells. Conversely, the lysosomal vacuolar H+-ATPase inhibitor blocks SAR-induced LCD. SAR further upregulates reactive oxygen species. Pom enhances SAR-induced direct and indirect killing even in MM cells resistant to Pom/Len. Taken together, SAR is the first therapeutic monoclonal antibody mediating direct cytotoxicity against MM cells via multiple mechanisms of action. Our data show that Pom augments both direct and effector cell-mediated MM cytotoxicity of SAR, providing the framework for combination clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab has been shown to directly induce apoptosis in MM cells without the need for crosslinking agents or effector cells. This unique ability contributes to its effectiveness in killing MM cells [167, 168].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [168]
Citations
Cites
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationLysosomal cell death at a glance
Aits, S., & Jäättelä, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.091181 · Cited by 667
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519
Tai, Y., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J. L., Yates, J. W., Gliddon, L., Fieles, W. E., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 492
Self-citationTai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationDroga-Mazovec, G., Bojič, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, G. S., Stoka, V., Turk, V., & Turk, B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802513200 · Cited by 399
Petersen, N. H. T., Olsen, O. D., Groth‐Pedersen, L., Ellegaard, A., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.003 · Cited by 344
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M. R., Munshi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.115 · Cited by 310
Self-citation
Cited by
Sorted by citations
Items 101–200 of 211
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
D’Agostino, M., Innorcia, S., Boccadoro, M., & Bringhen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218192 · Cited by 28
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Raimondo, F. D., & Giuliani, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684561 · Cited by 24
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Kassem, S., Diallo, B., El-Murr, N., Carrié, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Reguigne-Arnould, I., et al. (2022) · Blood · doi:10.1182/blood.2021012448 · Cited by 24
Špıčka, I., Moreau, P., Martin, T. G., Facon, T. T. F., Martınez, G., Oriol, A., Koh, Y., Lim, A. B. M., Mikala, G., Rosiñol, L., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13835 · Cited by 24
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Deciphering the bone marrow microenvironment’s role in multiple myeloma immunotherapy resistance
Iannozzi, N. T., Giuliani, N., & Storti, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613265 · Cited by 26
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23
Boissel, N., Chevallier, P., Doronin, V., Griškevičius, L., Maschan, A., McCloskey, J. K., Rambaldi, A., Rossi, G., Sokolov, A. N., Wartiovaara‐Kautto, U., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4478 · Cited by 22
Usmani, S. Z., Karanes, C., Bensinger, W., D’Souza, A., Raje, N. S., Tuchman, S. A., Sborov, D. W., Laubach, J. P., Bianchi, G., Kanagavel, D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01262-w · Cited by 22
Self-citationKoiwai, K., Cheikh, R. E., Thai, H., Brillac, C., Fau, J., Veyrat‐Follet, C., Risse, M., de Velde, H. J. V., Sémiond, D., & Nguyen, L. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12666 · Cited by 21
Qing, Y., Guo, Y., Zhao, Q.-W., Hu, P., Li, H., Yu, X., Zhu, M., Wang, H., Wang, Z., Xu, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1229 · Cited by 21
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date
Richter, J. R., Sanchez, L. J., & Thibaud, S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.04.004 · Cited by 20
Richardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20
Self-citationXu, Q., Liu, X., Mohseni, G., Hao, X., Ren, Y., Xu, Y., Gao, H., Wang, Q., & Wang, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02664-1 · Cited by 20
Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
Luca, F. D., Allegra, A., Chio, C. D., Previti, S., Zappalà, M., & Ettari, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043136 · Cited by 21
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
Xing, L., Liu, Y., & Liu, J. (2023) · Cancers · doi:10.3390/cancers15082240 · Cited by 19
Aljabri, A., Vijayan, V., Stankov, M. V., Nikolin, C., Figueiredo, C., Blasczyk, R., Becker, J. U., Linkermann, A., & Immenschuh, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1319-5 · Cited by 20
Sunami, K., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., Ikeda, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14657 · Cited by 19
Suzuki, K., Nishiwaki, K., & Yano, S. (2021) · Cancers · doi:10.3390/cancers13194867 · Cited by 16
A new era of immune therapy in multiple myeloma
Tai, Y., & Anderson, K. C. (2016) · Blood · doi:10.1182/blood-2016-06-719856 · Cited by 17
Self-citationEvolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 17
Sun, H., Martin, T. G., Marra, J. D., Kong, D., Keats, J., Macé, S., Chiron, M., Wolf, J. L., Venstrom, J. M., & Rajalingam, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002958 · Cited by 17
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
Gambles, M. T., Li, J., Wang, J., Sborov, D. W., Yang, J., & Kopec̆ek, J. (2021) · Molecules · doi:10.3390/molecules26154658 · Cited by 17
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Wang, A., Song, Z., Zheng, G., Nicolazzi, C., Fromm, J. R., Shehu, E., Srinivasan, S. S., Chen, X., Zhu, C. Y., Blondel, M. C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0058 · Cited by 19
Self-citationMartin, T. G., Mikhael, J. R., Hájek, R., Kım, K., Suzuki, K., Hulin, C., Garg, M. K., Quach, H., Sia, H., George, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006713 · Cited by 17
Chami, B., Okuda, M., Moayeri, M., Pirenne, F., Hidaka, Y., Nambiar, A., Song, Z., Bedel, O., Zhang, B., Hopke, J., et al. (2022) · Transfusion · doi:10.1111/trf.17137 · Cited by 16
Self-citationFacon, T. T. F., Moreau, P., Baker, R. I., Min, C., Leleu, X. P., Mohty, M., Karlin, L., Armstrong, N. M., Tekle, C., Schwab, S., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283073 · Cited by 16
Reprint of “Immunomodulatory effects of CD38-targeting antibodies”
van de Donk, N. W. C. J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.02.002 · Cited by 16
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16
Self-citationMonoclonal Antibodies in the Treatment of Multiple Myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.002 · Cited by 16
Richardson, P. G. G., Perrot, A., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., Huang, S., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284325 · Cited by 14
Self-citationLesokhin, A. M., LeBlanc, R., Dimopoulos, M. A., Capra, M., Carlo‐Stella, C., Karlin, L., Castilloux, J., Forsberg, P. A., Parmar, G., Tosikyan, A., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5753 · Cited by 14
Application of CD38 monoclonal antibody in kidney disease
Chen, Z., Xu, Q., & Shou, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382977 · Cited by 13
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Tannoury, M., Garnier, D., Susín, S. A., & Bauvois, B. (2022) · Cancers · doi:10.3390/cancers14246026 · Cited by 13
Antibody mimicry, receptors and clinical applications
Horenstein, A. L., Chillemi, A., Quarona, V., Zito, A., Mariani, V., Faini, A. C., Morandi, F., Schiavoni, I., Ausiello, C. M., & Malavasi, F. (2016) · Human Antibodies · doi:10.3233/hab-160305 · Cited by 14
Practical Considerations for Antibodies in Myeloma
Laubach, J. P., van de Donk, N. W. C. J., Davies, F. E., & Mikhael, J. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205443 · Cited by 13
Therapeutic antibodies for multiple myeloma
Ishida, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy133 · Cited by 13
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Braunstein, M. J., Weltz, J., & Davies, F. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1909469 · Cited by 13
Boosting Immunity against Multiple Myeloma
Lopes, R., Ferreira, B. V., Caetano, J., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13061221 · Cited by 11
Safety issues and management of toxicities associated with new treatments for multiple myeloma
Brioli, A., Mügge, L., Hochhaus, A., & von Lilienfeld‐Toal, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284584 · Cited by 10
Chandran, S., & Vincenti, F. G. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.10.005 · Cited by 9
Carlo‐Stella, C., Zinzani, P. L., Sureda, A. M., Araújo, L. F., Casasnovas, O., Carpio, C. D. C., Yeh, S., Bouabdallah, K. K., Cartron, G., Kim, W. S., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3089 · Cited by 9
Novel therapeutic targets in Waldenstrom macroglobulinemia
Paulus, A., Ailawadhi, S., & Chanan-Khan, A. A. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.020 · Cited by 9
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Salah, A. N., Hashem, A. H., Zaki, M. B., Abulsoud, A. I., Atta, A. M., Elkalla, W. S., Moustafa, H. A. M., El‐Dakroury, W. A., El-Tokhy, F. S., ElBoghdady, J. A., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70163 · Cited by 9
Djebbari, F., Poynton, M., Sangha, G., Anderson, L., Maddams, R., Eyre, T. A., Vallance, G. D., Basu, S., & Ramasamy, K. (2022) · Hematology · doi:10.1080/16078454.2022.2028978 · Cited by 8
Rachedi, F., Koiwai, K., Gaudel‐Dedieu, N., Sébastien, B., Thai, H., Brillac, C., Fau, J., Nguyen, L., de Velde, H. J. V., Veyrat‐Follet, C., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12789 · Cited by 8
El-Shershaby, H. M., Farrag, N. S., Ebeid, N. H., & Moustafa, K. A. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122019 · Cited by 8
Smith, W. S., Johnston, D. A., Holmes, S. E., Wensley, H. J., Flavell, S. U., & Flavell, D. J. (2019) · Toxins · doi:10.3390/toxins11020127 · Cited by 8
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Storti, P., Costa, F., Marchica, V., Burroughs-Garcìa, J., Palma, B. D., Toscani, D., Eufemiese, R. A., & Giuliani, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092864 · Cited by 7
Sunami, K., Ikeda, T., Huang, S., Wang, M., Koh, Y., Min, C. K., Yeh, S., Matsumoto, M., Uchiyama, M., Iyama, S., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.005 · Cited by 7
Mustafa, N. B., Azaman, M. I. B., Ng, G. G. K., & Chng, W. J. (2022) · Biomolecules · doi:10.3390/biom12091261 · Cited by 8
Efficacy and safety of elotuzumab for the treatment of multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1279603 · Cited by 6
Current and prospective antibody-based therapies in multiple myeloma
Bryer, E. J., DeStefano, C. B., & Kazandjian, D. G. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.11.002 · Cited by 6
Richter, J. R., Lin, P. L., García-Horton, V., Guyot, P., Singh, E., Zhou, Z., Sievert, M., & Taiji, R. (2023) · Cancer Medicine · doi:10.1002/cam4.5584 · Cited by 6
Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Lee, H. C., Mark, T. M., & Shah, J. J. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0312-7 · Cited by 6
Liu, N., Xie, Z., Li, H., & Wang, L. (2024) · Oncology Letters · doi:10.3892/ol.2024.14391 · Cited by 6
Self-citationKrohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908093 · Cited by 5
Li, S., Chen, D., Yang, Y., Guo, H., Liu, D., Sun, N., Bai, X., Wang, K., Li, T., Li, G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398508 · Cited by 5
Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Lee, H. C., & Weber, D. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.512 · Cited by 6
Treatment of double-refractory multiple myeloma
Семочкин, С. В. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-3-58-73 · Cited by 5
Delgado, J., Zienowicz, M., van Hennik, P. B., Moreau, A., Gisselbrecht, C., Enzmann, H. G., & Pignatti, F. (2021) · The Oncologist · doi:10.1002/onco.13892 · Cited by 4
Shah, B., Gray, J., Abraham, I. L., & Chang, M. M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221107850 · Cited by 4
Sunami, K., Fuchida, S., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3105 · Cited by 4
Future therapeutic options for patients with Waldenström macroglobulinemia
Castillo, J. J., Hunter, Z. R., Yang, G., Argyropoulos, K. V., Palomba, M. L., & Treon, S. P. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.021 · Cited by 4
Self-citationVision Statement for Multiple Myeloma: Future Directions
Anderson, K. C. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_2 · Cited by 4
Self-citationSteinhardt, M., Zhou, X., Krummenast, F., Meckel, K., Nickel, K., Böckle, D., Messerschmidt, J., Knorz, S., Dierks, A., Heidemeier, A., et al. (2020) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738420980258 · Cited by 4
Daratumumab combinations: what can we learn?
Kastritis, E., & Dimopoulos, M. A. (2017) · Blood · doi:10.1182/blood-2017-07-793349 · Cited by 4
Klein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 4
Immunotherapy in Multiple Myeloma
Gleason, C. L., & Catamero, D. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.011 · Cited by 3
CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Verina, D., Fowler, A., Louw, K., Barnes, Y., & Vickroy, A. M. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.05.001 · Cited by 3
Thai, H., Koiwai, K., Shitara, Y., Kazama, H., Fau, J., Sémiond, D., & Veyrat‐Follet, C. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12947 · Cited by 3
Shimazu, Y., Kanda, J., Onda, Y., Fuchida, S., Ohta, K., Shimura, Y., Kosugi, S., Yamamura, R., Matsuda, M., Hanamoto, H., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03711-8 · Cited by 3
Anticorps anti-CD38 dans le myélome multiple
Moreaux, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019198 · Cited by 3
Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) for the Management of Relapsed Multiple Myeloma
Banerjee, R. K., Lo, M., & Martin, T. G. (2021) · Future Oncology · doi:10.2217/fon-2021-0778 · Cited by 3
Martin, T. G., Capra, M., Mohty, M., Suzuki, K., Quach, H., Cavo, M., Moreau, P., Dimopoulos, M. A., Yong, K., Tekle, C., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.005 · Cited by 3
Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?
Oliva, S., & Palumbo, A. P. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201061 · Cited by 3
Ishida, T., Ito, S., Tanaka, J., Uchiyama, M., Kawano, Y., Moreau, P., Martin, T. G., Risse, M., Tada, K., Suzuki, K., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac137 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2
Regidor, B. S. S., Jew, S. K., Goldwater, M., Beatty, B. M., Bujarski, S. E., ElSayed, A., Danis, R., Kim, S., Swift, R. A., Schwartz, G., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14057 · Cited by 2
Pitoy, A., Desmée, S., Riglet, F., Thai, H., Klippel, Z. K., Sémiond, D., Veyrat‐Follet, C., & Bertrand, J. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13206 · Cited by 2
Zhang, F., Dong, Y., Yang, Z., Guo, C. J., Zhang, X., Shang, Y., Li, L., Gao, M. Y., & Pang, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114831 · Cited by 2
Wilde, S. C.-D., Plawny, L., & Berchem, G. (2023) · Hematology · doi:10.1080/16078454.2023.2182098 · Cited by 2
Yu, T., Qiao, C., Lv, M., & Tang, L. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0524-8 · Cited by 2
Precision Medicine in Therapy of Non-solid Cancer
Schmidts, I., Haferlach, T., & Hoermann, G. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_608 · Cited by 1
Sun, M. Y., Jing, H., Qu, X., Dong, F., Li, Y., Feng, Z., Ziti‐Ljajic, S., Sémiond, D., Li, L., Qi, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59186-1 · Cited by 1
Self-citationPiggin, A., & Prince, H. M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1924052 · Cited by 1
Increased expression of CEP72 predicts poor prognosis in multiple myeloma
Guo, D., Lu, J., Ji, H., Lin, Z., Hong, L., Huang, H., & Liu, H. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14024 · Cited by 1
Suzuki, K., & Yano, S. (2023) · Life · doi:10.3390/life13112229 · Cited by 1
Ryabukhina, Y. E., Zeynalova, P. A., Abbasbeyli, F. M., Тимофеева, О. Л., Valiev, T. T., Александровна, К. Н., & Жуков, А. Г. (2023) · Oncohematology · doi:10.17650/1818-8346-2023-18-4-90-103 · Cited by 1
Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma
Abramson, H. N. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94196 · Cited by 1
Bones of Contention: Reflections on Osteoarchaeology and the Baltic Region
Bartosiewicz, L. (2020) · Archaeologia Lituana · doi:10.15388/archlit.2019.21.1 · Cited by 1
Vulnerability of invasive glioma cells to lysosomal membrane instabilizationPreprint
Joncour, V. L., Hyvönen, M. L. K., Filppu, P., Turunen, S. P., Sihto, H. J., Burghardt, I., Joensuu, H., Tynninen, O., Jääskeläinen, J. E., Weller, M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/276402
Elucidation of the cell signaling pathways mediating innate immunity and host-pathogen interactions
Nabar, N. R. (2019) · Figshare
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma
Wilmoth, J., Colson, K., Dubin, F., & Kellam, C. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.706-712
Dimopoulos, M. A., Richardson, P. G. G., & Lonial, S. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.005
Self-citationRetractedRadionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-2
Research Progress of Anti-CD38 Monoclonal Antibody Isatuximab in the Treatment of Multiple Myeloma
田, 闻. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.126842
Metadata
- Authors
- Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., Qiu, L., Richardson, P., Munshi, N. C., Tai, Y.-T., & Anderson, K. C.
- Affiliations
- Second Military Medical University (CN)
- Dana-Farber Cancer Institute (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Tai, Y-T
- Venue
- Leukemia
- Published
- 2015-09-04
- Volume
- 30
- Issue
- 2
- Pages
- 399-408
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1916436059
- Cited by
- 219
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 17 · 2023: 25 · 2022: 45 · 2021: 33 · 2020: 31 · 2019: 20 · 2018: 11 · 2017: 16 · 2016: 16 · 2015: 1
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-10-22)
- Open access
- closed
- Licence
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15)
- U.S. Public Health Service (R01-050947)
- National Cancer Institute (P01-CA078378, P50CA100707)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- pomalidomide, multiple myeloma, anti-CD38 monoclonal antibody, homotypic aggregation, lysosomal membrane permeabilization, cathepsin B, LAMP1, reactive oxygen species, F(ab')2 fragments, TP53 mutation, lenalidomide resistance, combination therapy, retracted article
- MeSH terms
- Actins, Humans, Lysosomes, Membrane Glycoproteins, Multiple Myeloma, Thalidomide, Genes, p53, Apoptosis, Reactive Oxygen Species, Membrane Microdomains, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
